JLK
JLK is a South Korean public medical AI company that builds FDA-cleared, PMDA-approved computer vision software for detecting brain hemorrhages and infarctions on non-contrast CT scans, sold via subscription to hospital systems across Korea, the US, and Japan.
- Company typePrivate
- Founded2014
- HeadquartersYeoksamdong, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What JLK does
JLK is a South Korea-based artificial intelligence medical software company that develops and commercializes computer vision tools for stroke detection on brain CT imaging. Its flagship product, NCCT (Non-Contrast CT), is an AI-powered diagnostic aid that analyzes non-contrast CT scans to detect brain hemorrhages and infarctions faster than manual radiological review, with regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in February 2025 and the US FDA. The company's broader portfolio includes multiple FDA-cleared stroke analysis and detection software modules — JLK secured five FDA 510(k) clearances for stroke detection solutions in 2025 — suggesting a platform-plus-modules architecture that can be deployed individually or bundled for hospital customers.
JLK monetizes its software primarily through a subscription model sold to large hospital systems and academic medical centers. The anchor reference customer is Asan Medical Center, one of South Korea's leading hospitals, which adopted JLK's stroke AI solution on a multi-year subscription contract in January 2026 — an event that drove an 11% stock gain and signaled enterprise-grade demand validation. JLK distributes its solutions through direct enterprise sales to hospital systems, with regulatory clearances serving as the primary enabler of geographic expansion across South Korea, the United States, and Japan. The company is publicly listed on KOSDAQ (ticker A322510) and employs 101–250 people.
JLK firmographics
Firmographics- Name
- JLK
- Legal name
- JLK
- Website
- https://jlkgroup.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- JLK is a South Korean public medical AI company that builds FDA-cleared, PMDA-approved computer vision software for detecting brain hemorrhages and infarctions on non-contrast CT scans, sold via subscription to hospital systems across Korea, the US, and Japan.
- Ownership category
- akta.pro rank
JLK industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Medical Laboratories (621511), Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industry
- Stroke & Vascular Neurology (HLAKAIAG)
Keywords
Where JLK is headquartered
LocationHeadquarters
- HQ city
- Yeoksamdong
- HQ country
- South Korea
- HQ region
- Asia
Markets served
JLK business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- AI Software Subscription: JLK provides its stroke AI solution on a subscription model to healthcare institutions such as Asan Medical Center
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Subscription-based pricing model for hospital adoption |
Go-to-market motion1 record
Distribution channels1 record
JLK product offering
Product offeringCore offering
JLK develops and sells AI-powered medical imaging software for stroke detection and diagnosis. Its core products analyze non-contrast CT (NCCT) brain scans to identify hemorrhages and infarctions, and are deployed at hospitals and medical centers on a subscription basis. The company has secured multiple FDA 510(k) clearances and Japan PMDA approval to commercialize its stroke AI suite in the US and Japanese markets.
Product overview
JLK is a Korean medical AI company specializing in stroke detection and analysis solutions. The company offers a portfolio of AI-powered medical imaging products, primarily focused on stroke diagnosis using CT scan analysis. The core product line includes NCCT (Non-Contrast CT), a stroke diagnosis tool that detects brain hemorrhages and infarctions, along with related stroke analysis and detection software solutions. JLK operates on a platform-plus-modules architecture, with multiple FDA-cleared stroke detection solutions that can be deployed individually or as integrated offerings. The company also offers its stroke AI solution via subscription model to healthcare providers like Asan Medical Center.
Differentiator
Problem solved
Functional benefit
Brands
- NCCT: AI-powered stroke diagnosis tool that aids in faster detection of brain hemorrhages and infarctions using non-contrast CT scans.
Products and services
- NCCT (Non-Contrast CT) Stroke Diagnosis Tool AI-powered stroke diagnosis software that analyzes non-contrast CT (NCCT) brain scans to detect hemorrhages and infarctions. Designed for hospital radiology and emergency stroke workflows, approved by Japan's PMDA and cleared by the US FDA for clinical use.
- Stroke Analysis Software (FDA Cleared) FDA-cleared AI imaging software for stroke detection and monitoring. Enables automated analysis of medical imaging data for hospitals and healthcare providers in the US market.
- Stroke Detection Solutions Portfolio of AI-powered medical imaging software solutions for stroke detection and analysis, offered to hospital systems globally. Deployed via multi-year subscription contracts with healthcare institutions such as Asan Medical Center.
Quantifiable outcome
- 11% stock gain after Asan Medical Center subscription adoption
- +2 more outcomes
Companies that use JLK
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
JLK technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
JLK partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Asan Medical CentercoreAsan Medical Center, one of South Korea's leading medical institutions, adopted JLK's stroke AI solution on a subscription model. This partnership drove an 11% stock gain for JLK and represents significant market validation of JLK's AI stroke detection technology in a major hospital system.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
JLK competitors and assessment
Company assessmentDirect peers
- RapidAI: Specializes in AI-based stroke and aneurysm imaging analysis using CT and MRI; competes head-to-head with JLK in hospital stroke workflows globally.
- VUNO: Another Korean medical AI peer named in JLK's competitive landscape; offers AI diagnostic solutions across multiple imaging modalities with regulatory approvals in major Asian markets.
- Lunit: Korean medical imaging AI company explicitly named alongside JLK in the data; competes in AI-driven cancer imaging and is expanding into broader diagnostic AI, with deeper funding and broader modality coverage than JLK.
- Aidoc: AI medical imaging company with FDA-cleared solutions across multiple acute care workflows including stroke; competes for the same hospital imaging AI budgets and FDA regulatory slots.
- Brainomix: UK-based stroke imaging AI company (e.g., e-Stroke suite) with CE-marked and FDA-cleared products; direct competitor in AI-based non-contrast CT stroke assessment.
- Viz.ai: US-based leader in AI-powered stroke detection and care coordination; directly competes with JLK in the same stroke workflow using CT imaging, with established FDA clearances and US hospital footprint.
- Coreline Soft: Korean medical imaging AI company explicitly listed as a peer of JLK; focused on chest CT and broader radiology AI, providing direct competition for hospital imaging AI budgets.
Regional players
- Infervision: China-based medical imaging AI company with broad radiology AI offerings; overlaps with JLK's stroke detection category but serves primarily the Chinese and APAC market.
Emerging players
- Avicenna.ai: Specializes in AI for medical imaging including stroke and pulmonary embolism detection; an emerging competitor with narrower footprint than incumbents but overlapping use case.
Broad incumbents
- Nanox (Zebra Medical Vision): Acquired Zebra Medical Vision to build a broader AI imaging portfolio across multiple clinical conditions; competes in hospital AI imaging broadly rather than specializing in stroke.
Market position
Competitive moat3 records
Key highlights6 records
Customer concentration
JLK social profiles
Digital presenceJLK compliance and trust
Trust signalCompliance2 records
JLK financial estimates
Financial estimateRevenue estimate
Valuation estimate
JLK leadership team
Management profileNumber of profiles
JLK funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
JLK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about JLK
What does JLK do?
JLK develops and sells AI-powered medical imaging software for stroke detection and diagnosis. Its core products analyze non-contrast CT (NCCT) brain scans to identify hemorrhages and infarctions, and are deployed at hospitals and medical centers on a subscription basis. The company has secured multiple FDA 510(k) clearances and Japan PMDA approval to commercialize its stroke AI suite in the US and Japanese markets.
Is JLK a public or private company?
JLK is a private company. It is classified as public and is currently operating.
When was JLK founded?
JLK was founded in 2014. It employs 101 to 250 people.
Where is JLK based?
JLK is headquartered in Yeoksamdong, South Korea, in the Asia region.
How does JLK make money?
One revenue line is on record: AI Software Subscription.
Who are JLK's main competitors?
Direct peers on record are RapidAI, VUNO, Lunit, Aidoc, Brainomix, Viz.ai and Coreline Soft. Infervision is listed as a regional player. Avicenna.ai is listed as an emerging player. Nanox (Zebra Medical Vision) is listed as a broad incumbent.
Does JLK have an API?
No public API is recorded for JLK.
What industry is JLK in?
JLK's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 621511 and its SIC code is 8071.